REDUCE-AMI Journal Club

The New England Journal of Medicine published the REDUCE-AMI trial in April 2024. This post is a journal club breaking down the REDUCE-AMI trial and what change it may bring to our clinical practice.

Thanks to High Powered Medicine (@highpoweredmedicine on Instagram) for helping construct this post!

Link to the trial on NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa2401479

Become a paid subscriber: All profits go to Alzheimer's and cancer research!

Background/Overview

Title: Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction

Citation: Yndigegn T, Lindahl B, Mars K, et al. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. N Engl J Med. 2024;390(15):1372-1381.

Objective: To determine the effect of long-term beta-blocker therapy on cardiovascular outcomes in patients post-myocardial infarction with preserved ejection fraction.

Primary Efficacy Measure: Composite of all-cause mortality or myocardial infarction